## Abstract The objective of this study was to investigate the prevalence and timing of sudden gains over the course of brief, psychodynamically oriented treatment for generalized anxiety disorder (GAD). Data were used from two studies of brief (i.e., 16βsession) supportiveβexpressive psychotherapy
Improving homework compliance in the treatment of generalized anxiety disorder
β Scribed by Robert L. Leahy
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 90 KB
- Volume
- 58
- Category
- Article
- ISSN
- 0021-9762
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Generalized anxiety disorder is a chronic condition characterized by beliefs that worry prepares and protects, but that excessive worry is out of control. In this article, I review the cognitiveβbehavioral model of generalized anxiety, focusing specifically on problems related to excessive worrying. Noncompliance in selfβhelp homework is reflected in the patient's excessive focus on negative feelings, difficulty identifying automatic thoughts, demand for immediate results, and the belief that worries are realistic. Interventions for these problems are illustrated in the case of the treatment of a patient characterized by persistent worries, low selfβconfidence, procrastination, and avoidance. Β© 2002 Wiley Periodicals, Inc. J Clin Psychol/In Session 58: 499β511, 2002.
π SIMILAR VOLUMES
Ondansetron is a highly selective antagonist at the 5-HT 3 subtype of serotonin (5-HT) receptors . The 5-HT 3 receptors are the only receptors whose effects are mediated through the ion channels rather than the G-protein series . Ondansetron has no appreciable affinity for other 5-HT receptor subtyp
Individuals suffering from generalized anxiety disorder hold a variety of beliefs about the possible benefits of their worrying. The present article suggests that these beliefs emerge from both short-term and long-term experiences with negative reinforcement of the worry process. Elements of treatme
In a double-blind trial, 22 patients treated with 5 mg b.i.d. of the selective serotonin-S2 antagonist ritanserin for 4 weeks were compared with 26 patients treated with placebo for generalized anxiety disorder (DSM 111: 300.02). Symptoms were assessed using the Hamilton Anxiety Rating Scale (HARS)